# A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

> **NCT06088199** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 51 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Apremilast

## Key facts

- **NCT ID:** NCT06088199
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-24
- **Primary completion:** 2026-08-06
- **Final completion:** 2026-08-06
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06088199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06088199, "A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06088199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*